Target intelligence / Profile preview

Infected cell protein 34.5 (ICP34.5) (ICP34.5)

Target
ICP34.5
Molecular classification
Viral protein, Neurovirulence factor, Protein phosphatase 1 (PP1) regulatory protein
01

Overview

ICP34.5 is a 248-amino-acid neurovirulence factor protein produced by herpes simplex virus types 1 and 2 that serves as a critical determinant of viral pathogenesis, particularly in neuronal infections. The protein functions through multiple mechanisms to facilitate viral replication and evade host immune responses, including acting as a molecular scaffold that bridges protein phosphatase 1 and the translation initiation factor eIF2α to restore viral protein synthesis following infection-induced phosphorylation. Additionally, ICP34.5 inhibits autophagy through beclin1 binding, facilitates viral nuclear egress, and modulates mitochondrial dynamics in infected neurons. The deletion or mutation of ICP34.5 dramatically reduces viral virulence in the brain (by up to 10^6-fold) and impairs the establishment of latency, making it a significant target for antiviral therapeutic development. While not a human cellular target, understanding ICP34.5 function is crucial for developing antivirals and attenuated live vaccine candidates against herpes simplex virus infections.

Other names
Neurovirulence factor ICP34.5Viral protein ICP34.5γ1 34.5 gene productInfected-cell protein 34.5
02

Mechanism of action

ICP34.5 functions as a molecular bridge or scaffold protein that brings PP1 and eIF2α into proximity, enabling PP1-mediated dephosphorylation of eIF2α. This prevents the translation shutdown that normally occurs in response to viral infection.

03

Biological functions

Protein synthesis facilitation: ICP34.5 bridges protein phosphatase 1 (PP1) and eukaryotic initiation factor 2α (eIF2α) to mediate the dephosphorylation of eIF2α, which is phosphorylated by PKR during viral infection, thereby allowing viral protein synthesis to persistAutophagy inhibition: ICP34.5 binds beclin1 to inhibit autophagy, a cellular process involved in recycling or degrading cellular and microbial componentsViral nuclear egress: ICP34.5 facilitates viral nuclear egress by recruiting complement component 1 Q subcomponent-binding protein (C1QBP/p32) to the inner nuclear membrane, leading to rearrangement of the nuclear laminaMitochondrial dynamics modulation: Residues 68-87 of ICP34.5 bind mitochondrion-associated factors including PGAM5 and KEAP1, altering mitochondrial dynamics and reducing mitochondrial motility in neuronal axonsInnate immune evasion: ICP34.5 blocks multiple facets of the antiviral response and plays a role in blocking the interferon pathway
04

Disease associations

ICP34.5 is a key determinant of viral virulence in herpes simplex virus infections. The protein is essential for efficient viral replication in neuronal cells and contributes significantly to neurovirulence—HSV-1 ICP34.5 mutant viruses show LD50 values reduced as much as 10^6-fold in the brain. ICP34.5 is required for the establishment of latency and viral reactivation in neurons.
05

Safety considerations

ICP34.5 is essential for HSV neurovirulence, making it a challenging target for therapeutic intervention due to the need to avoid exacerbating infection outcomesThe multifunctional nature of ICP34.5 means that inhibiting one function may have unpredictable effects on other viral processesThe protein's role in blocking multiple innate immune pathways suggests that effective ICP34.5 inhibition could trigger complex immune responses
06

Biomarkers

ICP34.5 expression levels could serve as a biomarker for HSV infection severity and neuronal tropism, particularly in distinguishing productive infection from latent infection in neurons

Beyond the preview

Go deeper on Infected cell protein 34.5 (ICP34.5) (ICP34.5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Infected cell protein 34.5 (ICP34.5) (ICP34.5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call